Working With Clinical Trial Data Using AI Models

Clinical trials generate large, heterogeneous datasets spanning protocols, site records, electronic case report forms, adverse event narratives, and regulatory correspondence. This write-up outlines a generalized pattern synthesized from publicly discussed deployments across the industry rather than a single verified case study. Individual programme outcomes, cycle times, and data quality vary significantly based on therapeutic area, phase, and legacy systems.

The scope here is the data work that happens once a trial is running. Feasibility, site selection, and enrolment forecasting are a separate problem with their own failure modes, covered in AI for Trial Feasibility and Site Selection.

The problem

Even a mid-sized trial can involve dozens of sites, thousands of data points per participant, and hundreds of query documents. Clinical data managers and monitors spend much of their time on repetitive tasks: finding inconsistent entries across visits, coding free-text adverse events to MedDRA terms, and drafting data clarification requests [1].

Traditional approaches rely on static reports and manual review. That works at small scale, but as trials grow in complexity the lag between data collection and issue resolution increases. Delays in identifying a data-quality pattern can extend timelines and increase the cost of database lock.

How teams approach it

To reduce this friction, clinical operations and data science teams apply machine learning to in-flight trial data in validated, access-controlled environments. The approach typically combines three capabilities: anomaly detection, automated coding assistance, and narrative drafting support.

Anomaly-detection models compare newly entered values against participant-level histories and study-wide distributions to surface potential data-entry errors or protocol deviations for human review. Coding-assistance models suggest MedDRA preferred terms for verbatim adverse-event descriptions, leaving the final medical coding decision to trained coders or physicians [3]. Narrative-support models help draft participant narratives and query responses from structured data and source notes, with every output reviewed by qualified staff.

What the workflow looks like

A typical implementation connects to the clinical data management system through a validated pipeline:

• New eCRF entries are checked against learned distributions; outliers are routed to data managers as queries.
• Repeated query patterns are clustered so recurring site-level training gaps surface as one issue rather than fifty tickets.
• Verbatim adverse-event terms are sent to a coding-assistance model that returns ranked MedDRA term suggestions.
• Draft narratives and query responses are generated in a controlled authoring environment, with version control and audit trails.

Throughout the process, the model functions strictly as an analytical aid. Clinical, medical, and data-management staff retain complete authority and responsibility for all decisions that affect participant safety, data integrity, or regulatory submissions [4].

How it works in practice

• What data goes in. Trial datasets in their standard form — SDTM domains, ADaM analysis datasets, lab and vitals records, adverse-event tables — plus the free-text fields that sit alongside them, such as verbatim terms, comments and medical history.
• What the model predicts or ranks. Depending on the task: a coded term for a verbatim entry, a flag for a record that looks inconsistent with the rest of a subject's data, or a risk score identifying which sites or subjects warrant monitoring attention first.
• Technique or model family. Rule engines and statistical outlier detection for the structured checks, embedding similarity or classification models for coding verbatim text, and clustering or anomaly detection for site-level risk-based monitoring.
• How it is trained or validated. On locked historical studies where the correct coding and the real data issues are already known, split by study so nothing leaks across. Every deployment carries a documented intended use and validation appropriate to whether the output touches an analysis or only a work queue.
• What the team does with the output. Data managers work a prioritized query list, coders confirm suggested terms, and monitors visit the sites the signal points at. Nothing changes a dataset without a human action recorded in the audit trail.
• A representative example. Input: a verbatim adverse-event term "stomach upset after tablets". Output: a suggested MedDRA preferred term with a confidence score and the three nearest previously coded terms. The coder accepts or overrides it, and the audit trail records which.

Where it breaks

Deployments frequently stumble when teams feed identifiable patient data into general-purpose tools that lack appropriate controls. Any system that processes clinical data must operate inside a validated, access-controlled environment with de-identification or pseudonymization where required by protocol and regulation [5].

Another common failure point is over-reliance on model suggestions for medical coding or safety assessment. A suggested MedDRA term may be technically close to the verbatim term but medically inappropriate for the case; automated outputs must be reviewed by qualified personnel. Anomaly detection has the mirror-image risk: thresholds tuned too tightly bury data managers in false queries, and sites stop taking the flags seriously.

What good looks like

High-performing teams treat the model as a triage layer that narrows the human review queue rather than replacing it. They maintain clear escalation paths: any anomaly flagged as potentially serious, any coding suggestion with low confidence, and any draft narrative touching safety or regulatory language is reviewed by a qualified person before it is saved or submitted [6].

They also keep the system under formal change control. Model versions, training data cut-offs, and decision thresholds are documented, and re-validation is triggered when any of them change. Audit trails capture who reviewed each model-assisted output and what changes were made.

What to check before you start

• Confirm that the data environment meets GCP, 21 CFR Part 11, and any regional privacy requirements for the jurisdictions in which the trial operates [2].
• Define which decisions the model may assist with and which decisions remain reserved for qualified human staff.
• Establish a process for re-identifying and correcting model-assisted errors once they are detected in the database.
• Plan for model drift: data-entry behaviours and site practices change over the course of a trial.

Sources

1. US FDA, Artificial Intelligence and Medical Products.
2. ICH, E6(R3) Good Clinical Practice Guideline.
3. US FDA, Data Integrity and Compliance With Drug CGMP: Questions and Answers, guidance for industry.
4. European Medicines Agency, Reflection paper on the use of artificial intelligence in the medicinal product lifecycle.
5. Zhang et al., Accelerating drug discovery, development, and clinical trials by artificial intelligence, Med, 2024.
6. US FDA, General Principles of Software Validation, guidance for industry.